Gambro wins BiCart System Patent Trial in Australia

5/13/2004, 12:00 PM (Source: GlobeNewswire)

The Federal Court of Australia, New South Wales District Registry,
has found that a patent owned by Gambro's subsidiary, Gambro Lundia
AB, relating to Gambro's BiCart® dry concentrate system is infringed
by distribution in Australia of the Fresenius' biBag(TM) products and
Fresenius dialysis monitor systems when they are distributed in
conjunction with the biBag(TM) product. The Court found in favor of
Gambro Lundia AB and Gambro Pty. Ltd. (Australia) on 25 March 2004
and on 12 May 2004 entered an order requiring Fresenius Medical Care
AG's subsidiary, Fresenius Medical Care Australia Pty. Ltd., to stop
infringing activity including distribution in Australia of the biBag
product, and ordered an enquiry into the amount of damages due
Gambro. Fresenius Medical Care Australia Pty. Ltd. has been granted
leave to appeal the judgment and the court has stayed enforcement of
the order until the appeal has been decided.


About dialysis concentrates
Dialysis concentrates are central to the dialysis fluid delivery
system. Compared to liquid bicarbonate concentrates, the BiCart® dry
concentrate cartridge reduces the risk of contamination and bacterial
growth. A 650g BiCart cartridge replaces 9L of liquid concentrate,
reducing the need to lift heavy canisters and dramatically reducing
storage space and logistics costs. Since its introduction the BiCart®
cartridge has become the world standard in bicarbonate dialysis. Dry
concentrate cartridge products represent 20% of the concentrate
market worldwide today and the market is continuously growing.




For further information please contact:
Karin Avasalu, Vice President, Corporate Communications, tel.
+46-8-613 65 99, +46-70-513 65 99
Pia Irell, Vice President, Investor Relations, Corporate Finance,
tel. +46-8-613 65 91, +46-70-513 65 91
Kevin Smith, President Gambro Inc., Investor Relations US, tel.
+1-303 231 4750
View document
Gambro is a global medical technology and healthcare company with
leading positions in renal care - services and products - and blood
component technology. Gambro Healthcare is one of the leading
providers of kidney dialysis services in the world with 55,100
patients in more than 700 clinics worldwide. Gambro Renal Products
comprises dialyzers, dialysis machines, blood lines and dialysis
concentrates. Gambro BCT is the market leader in separation and
handling of blood components. The group, with 2003 revenues of SEK
26.1 billion (USD 3.2 billion), has about 21,200 employees in some 40
countries.
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.